Evidence map›Paper›PMID 31278860›Full record

ArticleJournal of cellular and molecular medicine2019

Qishen Yiqi Drop Pill, a novel compound Chinese traditional medicine protects against high glucose-induced injury in cardiomyocytes.

Shouyan Zhang, Hao Wang, Lixia Li, Xuewei Chang, Huifang Ma, Mingming Zhang, Xiaochun Qing, Lijun Zhang, Zhuo Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Functional Study ofPlants (Basel, Switzerland) · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shouyan ZhangDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China.ORCID 0000-0003-2902-1668
Hao WangDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China.ORCID 0000-0001-5694-1203
Lixia LiDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China.
Xuewei ChangDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China.
Huifang MaDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China.
Mingming ZhangDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China.
Xiaochun QingDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China.
Lijun ZhangDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China.
Zhuo ZhangDepartment of Cardiology, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang Institute of Cardio-cerebrovascular Diseases, Luoyang Key Laboratory of Cardiac-cerebro Tissue Injury and Repair, Luoyang, China.
Luoyang Central Hospital Affiliated to Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveQishen Yiqi Drop Pill (QSYQ) has been recognized as a potential protective agent for various cardiovascular diseases. However, the effect of QSYQ in cardiac complications associated with diabetes is not clear currently. In this study, we investigate whether QSYQ could exert cardiac protective effects against high glucose-induced injuries in cardiac H9c2 cells.

methodsH9c2 cells were exposed to 24 hours of high glucose in presence or absence of QSYQ and LY294002. Cell cytotoxicity, apoptosis, reactive oxygen species (ROS) generation, mitochondrial membrane potential and mitochondrial permeability transition pore (mPTP) opening were determined. Levels of bax, bcl-2, p53, cleaved caspase-3, PI3K and Akt were evaluated by Western blot.

resultsOur data indicated that QSYQ significantly increased the cell viability and decreased cytotoxicity. By analysing the apoptotic rate as well as the expression levels of cytoapoptosis-related factors including cleaved caspase-3, bax, bcl-2, and p53, we found that QSYQ could remarkably suppress apoptosis of cardiomyoblasts caused by high glucose. In addition, it also showed that QSYQ reduced the generation of ROS. We further found that QSYQ treatment could inhibit the loss of mitochondrial membrane potential and mPTP opening. Moreover, Western blot analysis showed enhanced phosphorylation of PI3K/Akt. The specific inhibitor of PI3K, LY294002 not only inhibited QSYQ induced PI3K/Akt signalling pathway activation, but alleviated its protective effects.

conclusionsIn summary, these findings demonstrated that QSYQ effectively protected H9c2 cells against the series injuries due to high glucose at least partially by activating the PI3K/Akt signalling pathway.

Indexed as

AnimalsApoptosisCell LineCell SurvivalDrugs, Chinese HerbalGlucoseMedicine, Chinese TraditionalMembrane Potential, MitochondrialMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreMyocytes, CardiacProtective AgentsRatsReactive Oxygen SpeciesSignal TransductionDrugs, Chinese HerbalGlucoseMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PoreProtective Agentsqishen yiqiReactive Oxygen Speciesdiabetes cardiomyopathyhigh glucose injuryPI3K/AktQishen Yiqi Drop Pilltraditional Chinese medicine

Identifiers

PMID31278860
PMCPMC6714141
OpenAlexW2954720955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.